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ABSTRACT
Introduction Driving is one of the main modes of 
transport with safe driving requiring a combination of 
visual, cognitive and physical skills. With population 
ageing, the number of people living with vision impairment 
is set to increase in the decades ahead. Vision impairment 
may negatively impact an individual’s ability to safely drive. 
The association between vision impairment and motor 
vehicle crash involvement or driving participation has yet 
to be systematically investigated. Further, the evidence 
for the effectiveness of vision- related interventions aimed 
at decreasing crashes and driving errors has not been 
synthesised.
Methods and analysis A search will be conducted for 
relevant studies on Medline (Ovid), EMBASE and Global 
Health from their inception to March 2020 without 
date or geographical restrictions. Two investigators 
will independently screen abstracts and full texts using 
Covidence software with conflicts resolved by a third 
investigator. Data extraction will be conducted on all 
included studies, and their quality assessed to determine 
the risk of bias using the Joanna Briggs Institute Critical 
Appraisal Tools. Outcome measures include crash risk, 
driving cessation and surrogate measures of driving 
safety (eg, driving errors and performance). The results 
of this review will be reported using the Preferred 
Reporting Items for Systematic Review and Meta- 
Analysis guideline. Meta- analysis will be undertaken for 
outcomes with sufficient data and reported following the 
Meta- analyses of Observational Studies in Epidemiology 
guideline. Where statistical pooling is not feasible or 
appropriate, narrative summaries will be presented 
following the Synthesis Without Meta- analysis in 
systematic reviews guideline.
Ethics and dissemination This review will only report on 
published data thus no ethics approval is required. Results 
will be included in the Lancet Global Health Commission 
on Global Eye Health, published in a peer- reviewed journal 
and presented at relevant conferences.
PROSPERO registration number CRD42020172153.
INTRODUCTION
According to the WHO,1 approximately 
1.35 million people die each year from road 
traffic injuries (RTIs), making it the eighth 
leading cause of death globally. Low- income 
and middle- income countries (LMICs) have 
lower rates of vehicle ownership compared 
with high- income countries (HIC), but over 
90% of RTI fatalities occur in LMICs with the 
highest death rates in Africa. Individuals from 
lower socioeconomic backgrounds living in 
HICs are also more likely to be involved in a 
road crash resulting in injuries. RTIs make up 
a major proportion of a country’s economic 
and social burden,2–4 and account for almost 
Strengths and limitations of this study
 ► Results from this systematic review will present up- 
to- date evidence for the influence of vision impair-
ment on road traffic injuries and the effectiveness of 
vision- related interventions.
 ► As there are no geographic restrictions in the cri-
teria for included studies, this review will capture a 
large portion of English- language publications in this 
research area with findings applicable to a global 
context.
 ► This review will not restrict the age of the target 
population allowing evidence on the impact of vision 
impairment and driving to be documented for all age 
groups.
 ► This review only looks at published studies in 
English, so research from non- English speaking 
countries will be missed, which could introduce bias.
 ► Another potential limitation is that interventions and 
outcome measures may be highly heterogeneous, 
which will affect the conclusions drawn from the 
results and prevent meta- analyses to be conducted 
for select outcomes.  on N
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30% of global injury- related disability.2 In the face of 
increasing motorisation, achieving absolute reductions in 
RTIs is a challenge, especially for vulnerable road users 
such as pedestrians and users of powered two and three 
wheeler vehicles. This challenge has a direct impact on 
the UN’s Sustainable Development Goals, in particularly 
Target 3.6 which called for a halving of global road deaths 
by 2020, and Target 11.2 which called for safe and sustain-
able transport systems, especially for vulnerable road 
users.5
Motor vehicle crashes (MVCs) and, by extension, RTIs, 
however, are preventable. Using the Haddon Matrix, an 
early theory describing the multifactorial nature of RTIs, 
MVCs are understood to involve host (human), agent 
(vehicles and equipment) and environmental (physical 
and socioeconomic) factors.6 This theory has since been 
used to build the Safe System Approach endorsed in the 
United Nations Road Safety Collaboration’s Decade of 
Action for Road Safety (2011–2020).7 In brief, the Safe 
System Approach aims to prevent MVCs which result in 
serious injuries or death by addressing four main pillars 
of focus: (1) safe roads, (2) safe speeds, (3) safe people 
and (4) safe vehicles.8 Road safety programmes, such as 
the Bloomberg Initiative for Global Road Safety (2015–
2019), focus on improving road safety through legislation 
in LMICs,9 thus addressing the environmental and agent 
risks of RTIs. Beyond road infrastructure and vehicle 
quality, human driving behaviours or ‘human factors’ also 
contribute to RTI rates and are an intrinsic part of the 
Safe System Approach. Safe driving requires individuals 
to have a range of physical, visual and cognitive skills. In 
addition to specific eye diseases, age- related functional 
declines across a range of domains, including vision, can 
reduce confidence in driving ability.10 Poor visual acuity 
and contrast sensitivity, visual field loss and glare sensi-
tivity have all been identified as potential factors contrib-
uting to poor driving performance and increased MVCs.11
Due to the high visual demands needed to drive safely, 
many countries have set federal- specific and/or state- 
specific standards for vision, mostly for visual acuity. Most 
countries accept that a visual acuity of at least 6/12 (0.50, 
20/40) in the better eye is considered as the requirement 
for driving. This threshold dictates jurisdictional control 
used to identify individuals with vision impairment and 
restrict their access to driving privileges. However, a 
systematic review by Dobbs suggested that licencing 
policies aimed at identifying at- risk older drivers may 
not be effective in decreasing crash rates.12 This may 
be because policies which govern licensure and vision 
screening vary significantly between and within coun-
tries. Further, evidence on their effectiveness is incon-
clusive.13 Conversely, in- person renewal policies, which 
include vision tests completed at licence renewal centres, 
have been shown to reduce crash rates in older drivers.14 
An American study analysing data from the National 
Highway Traffic Safety Administration Fatal Accident 
Reporting System found drivers aged 70 years and older 
who underwent visual acuity examinations during their 
licence renewals had lower fatal crash risks than their 
non- vision tested peers (risk ratio (RR) 0.93; 95% Cl 
0.89 to 0.97).15 However, the literature remains divided 
in its support for using visual acuity alone as a predictor 
of MVC involvement and high- risk driving behaviours.16 
A Cochrane review, updated twice, examined the bene-
fits of different vision screening procedures, such as 
visual acuity, visual field (central or peripheral), contrast 
sensitivity and useful field of view tests, in randomised 
controlled trials (RCTs) aimed at preventing RTIs and 
fatalities in older drivers.13 17 Unfortunately, no RCTs 
met the inclusion criteria for the review at the time these 
reviews were conducted.
There is substantial literature investigating how vision 
impairment, and other aspects of function, affect road 
safety. Measures of driving safety have included indirect 
measures such as performance on driving simulators, 
on- road driving assessments, naturalistic driving or in- ve-
hicle monitoring as well as direct measures of RTI and 
MVC rates from self- report or administrative datasets.18 19 
However, the evidence for the influence of vision loss on 
MVCs and the corresponding benefits of interventions 
to restore vision have not been systematically evaluated. 
Since older drivers have higher crash involvement20 
and greater prevalence of eye diseases due to natural 
age- related declines in vision,21 most research investi-
gate older drivers and their risks of crashes and injuries. 
However, it is important to document the impact of vision 
impairment across all age groups. Further, information is 
also needed about specific eye diseases and types of vision 
impairment to inform interventions to screen for poor 
vision in drivers, and interventions to rehabilitate vision, 
thereby enhancing driver safety and continued ability to 
drive. This is especially important for older adults who 
rely on driving to remain independent and connected 
with their community. The loss of the ability to drive and 
the eventual retirement from driving has been linked 
to higher symptoms of depression and poorer health in 
older adults.22
The aim of this systematic review is to: (1) describe 
the associations between vision impairment and risk of 
road crash involvement across the lifespan, and (2) eval-
uate vision- related interventions to reduce crash risk. 
Secondary outcomes are driving cessation and surrogate 
measures of crash risk such as on- road driving errors.
METHODS AND ANALYSIS
This systematic review protocol was drafted using the 
International Prospective Register of Systematic Reviews 
(PROSPERO) as a guideline and registered in PROS-
PERO (28 April 2020 (https://www. crd. york. ac. uk/ pros-
pero/ display_ record. php? ID= CRD42020172153)). Any 
changes to the protocol will be updated in PROSPERO. 
The protocol is prepared in accordance to the Preferred 
Reporting Items for Systematic review and Meta- Analysis 
Protocols statement (online supplemental appendix 1).23
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Eligibility criteria
This review will include human studies in the English 
language with full text available. Unlike the two previous 
Cochrane reviews which only included RCTs, this review 
will consider both interventional (RCTs and quasi- 
experimental) and observational (cohort, cross- sectional 
and case–control) studies. Systematic reviews will be 
included if meta- analysis was performed. For systematic 
reviews without meta- analysis, the reference list will be 
examined for potentially relevant articles, but the system-
atic review itself will not be included. All literature reviews, 
commentary articles, dissertations, abstracts, editorials 
and conference presentations will be excluded.
All studies must report on at least one of the outcome 
variables, described in the following section, which 
include MVC involvement and surrogate measures of 
driving safety such as driving errors and performance 
scores and driving cessation. Studies investigating either 
self- regulatory behaviours, such as night driving avoid-
ance and decreasing travel mileage, or self- reported 
measures of driving safety will be excluded. To obtain data 
on driving scores and performance, studies using on- road 
driving tests, which include closed- circuit routes and 
those combining both closed and real- road driving tracks, 
and naturalistic driving with in- vehicle monitoring will 
be included. Even though closed circuits may not reflect 
true on- road driving conditions, tests for common driving 
maneuverers such as road signage recognition, hazard 
recognition and avoidance, reversing and gap percep-
tion are able to be recreated on these routes.24 Driving 
errors and driving performance scores on the on- road 
driving tests can come from fitted in- vehicle monitoring 
technologies or trained observers. To restrict the scope 
of the study to direct measures of driving, studies which 
used driving simulators will be excluded as these are 
laboratory studies with only indirect measures of driving 
performance. MVC involvement cannot be measured 
and real- life driving experiences, such as limited expo-
sure to driving at night, in bad weather or during rush 
hour, may not be reflected in a simulation.25 Additionally, 
the validity of driving simulator results are highly depen-
dent on the type of simulation programme used and what 
kind of driving manoeuvre is being investigated.26 As this 
review is interested in the MVC involvement and driving 
abilities of individuals who drive and their habitual vision, 
studies which simulate impairments in vision will also be 
excluded.
The population of focus will be drivers of four- wheeled 
motorised vehicles such as cars, buses, and trucks. Unlike 
the two Cochrane reviews mentioned above, which only 
focused on older drivers, this review will include drivers 
of all ages. Studies of drivers who have specific medical 
conditions (eg, dementia, epilepsy, stroke and history of 
medical events such as syncope), or vision difficulties due 
to other medical factors (eg, hemianopia caused by brain 
damage) will not be included. Similarly, articles where 
vision status is not reported will be excluded.
Exposures in the included studies will encompass all 
types of vision impairment including visual acuity, contrast 
sensitivity, visual field loss as well as impairments associ-
ated with specific eye diseases including but not limited 
to glaucoma, cataracts, aged- related macular degenera-
tion, diabetic retinopathy, stereopsis disorders and colour 
vision deficiencies. Vision impairments can be catego-
rised by the specific eye diseases or by specific measures of 
vision which can negatively impact normal everyday func-
tioning. Even though it is not necessary for all included 
studies to report on vision- related interventions, studies 
which do report on interventions can include procedures 
such as vision screening, refractive correction, cataract 
surgery or other measures to restore and improve vision 
of drivers in order to maintain driving participation, 
promote safe driving and reduce risk of crash involve-
ment. The exposure comparators of included studies will 
be drivers who either do not have a vision impairment or 
have not received a vision- related intervention, within a 
timeframe chosen by the study in question.
Outcome measures
The primary outcome measure is MVC involvement 
including fatal MVC involvement. Data on crash involve-
ment and its severity can either come from self- reported 
surveys or data linkage with government and/or hospital 
records. Data from self- reported surveys will ensure that 
MVCs which were not serious enough to warrant a police 
or hospital report will be also be included.
Driving cessation and surrogate measures of driving 
safety will be the secondary outcomes. The surrogate 
measures of driving safety can include scores of driving 
performance from on- road driving tests or ‘naturalistic’ 
in- vehicle monitoring looking at manoeuvres such as lane 
keeping, braking and abidance of road signage like traffic 
lights, stop and give way signs. To account for differences 
in the criteria used by trained observers to evaluate the 
driving performance scores on on- road driving tests, 
a pass/fail threshold for driving performance scores 
specific to this review will be decided on by all investiga-
tors in order to synthesise results.
Search strategy
Electronic database search will be conducted by the 
Cochrane Eyes and Vision Information specialist (IG) 
on Medline (Ovid), EMBASE and Global Health from 
their inception to March 2020. Online supplemental 
appendices 2–4 show the search strategies for Medline, 
EMBASE and Global Health, respectively. Additional 
potentially relevant studies will be sought by experts in 
the field by checking the reference lists and citations of 
included studies, and checking the reference list of narra-
tive systematic reviews identified in the search.
Data collection and analysis
Data management and selection
Each title and abstract will be screened by two investiga-
tors independently (from HN, KR, JR, JHZ, SM, JF, GFK) 
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using Covidence systematic review management soft-
ware (Veritas Health Innovation, Melbourne, Australia; 
available at https://www. covidence. org/ home). Full- 
text review of potentially relevant articles will then be 
conducted by two investigators independently. Discrep-
ancies will be discussed and resolved via consultation with 
a third investigator.
Data extraction
Data extraction will be completed independently by two 
investigators (from among the same seven investigators). 
Data from included studies will be extracted using adap-
tions of the Joanna Briggs Institute (JBI) template for 
systematic reviews and observational studies (including 
cohort, cross- sectional and case–control studies).27 
Adapted Cochrane templates will be used to extract data 
from randomised controlled trials and quasi- experimental 
studies.28
Quality assessment
A quality assessment to determine an overall risk of bias 
will be carried out on all included studies independently 
by two investigators (from the seven investigators 
mentioned previously). Conflicts will be resolved by a 
third investigator. Relevant JBI critical appraisal tools will 
be used to evaluate randomised controlled trials, quasi- 
experimental studies, systematic reviews, cohort studies, 
cross- sectional studies and case–control studies.29
Data synthesis strategy
Measures of association between vision impairment/
vision- related interventions and MVC involvement, 
driving cessation and surrogate measures of driving safety 
will be summarised according to the outcome measures 
reported in the primary studies. In particular, appro-
priate HR, RR and OR for binary data and (standardised) 
mean differences for continuous data will be statistically 
pooled. When the same outcome is reported as dichot-
omous data in some studies and as continuous data in 
others, these studies will be pooled by expressing the 
ORs as standardised mean differences and vice versa.30 P 
values of the driving outcomes will also be reported where 
appropriate.
Where it is not possible or suitable to statistically pool 
the studies, a narrative summary of the findings will be 
used instead. Narrative summaries will follow the Synthesis 
Without Meta- analysis reporting guidelines.31 Heteroge-
neity across all included studies with sufficient data will 
be assessed clinically, methodologically and statistically. 
Clinical heterogeneity will be assessed by comparing the 
differences between the participant characteristics (eg, 
age, sex, eye disease, driving mileage, licence status or 
other available measures of driving exposure), interven-
tions and outcomes measured. The design and quality of 
included studies will be compared to assess methodolog-
ical heterogeneity. Statistical heterogeneity across studies 
will be explored by formal statistical test of heterogeneity, 
subgroup analyses and, if feasible, by meta- regression. 
Inconsistency of the effect sizes across the studies will be 
assessed by the proportion of variability in the effect sizes 
of the included studies due to heterogeneity (and not by 
sampling error) using I2. Estimates will be pooled using 
random effects models with fixed- effect models, results 
also reported regardless of the values of I2, and prediction 
intervals to allow for expected effects of future studies to 
be extrapolated based on the current evidence.32
The following outcomes will be assessed using meta- 
analysis where feasible according to data availability: crash 
involvement, driving cessation and surrogate measures of 
unsafe driving, that is, driving errors and driving perfor-
mance. Furthermore, meta- analyses for each of the different 
eye diseases, and studies from LMIC settings will also be 
performed independently for each outcome of interest if 
possible. As there is no age restriction on the focus popula-
tion, results on age will be synthesised by assessing specific 
subgroup analysis and/or meta- regression, which may 
partially explain heterogeneity across studies in the pooled 
effect size. The Meta- analysis of Observational Studies in 
Epidemiology guidelines will be used to guide reporting.33 
The Grading of Recommendations Assessment, Develop-
ment and Evaluation approach will be used to assess the 
quality of evidence in the meta- analyses.34
Sensitivity analysis will be performed on low risk of bias 
studies, while the meta- analysis will include all studies. This 
will assist with verifying the strength of the study findings 
and to assess how different methodologies, sample sizes and 
statistical analyses have affected this study’s results. Further-
more, funnel plots will be used to assess publication bias.
Corresponding authors from publications dated 
2010 onwards with missing data of potential use will be 
approached via email, up to a maximum of three attempts, 
to request further information. Any unobtainable data will 
be noted alongside all attempts to contact the respective 
authors. Even though only available data will be used for the 
meta- analysis, the effects of any missing data will be consid-
ered and their effects discussed in the overall final review.
Patient and public involvement
This review will only be looking at the existing published liter-
ature. No patient or public involvement is currently planned 
for the design and execution of this review, however public 
participation may be sought for this review’s dissemination.
ETHICS AND DISSEMINATION
As this review will only be focusing on the currently 
published literature, ethics approval is not required. 
Results from this systematic review will be published in 
an open peer- reviewed journal and will form part of the 
ongoing Lancet Global Health Commission on Global Eye 
Health.35 Where relevant, it will also be presented at 
conferences.
DISCUSSION
Significance of this review
The findings of this systematic review may influence future 
road safety and licencing policies on driving for drivers 
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with vision impairment. By understanding the visual 
factors contributing to MVCs, vision- related screening 
tests for licencing may be reconsidered and updated to 
increase relevance to driving safety. As mentioned previ-
ously, most reviews on driving with vision impairment 
have been limited to older drivers and the effects of 
different licencing renewal procedures on their ability 
to drive. Even though older drivers are at higher risk,21 
this review will seek to capture data on driving and vision 
impairment for all age groups.
The eligibility criteria for included studies for this 
review will ensure that global data on vision and driving 
will be captured. Currently, MVC- related societal burdens 
and injury- related disability burdens in LMICs are poorly 
understood, which may partially explain why cost- effective 
interventions in these countries are rarely undertaken.2 
LMICs tend to focus on legislative interventions, followed 
by education/training workshops, public awareness 
campaigns, enforcement measures, speed control and 
infrastructure improvements.36 Current data on human 
factors specifically related to vision impairment in LMICs 
reported in this review may inform future evidence- based 
policies on licencing and/or screening policies to address 
these gaps.
Results from this review may also provide additional 
evidence on the impact of eye disease- specific interven-
tions on quality of life factors, especially those related to 
driving and the ability to drive. Interventions to improve 
and optimise vision are needed for drivers, in recogni-
tion of the importance of continued safe driving. This 
greater awareness in turn will also provide evidence for 
policies around road safety for individuals with vision 
impairments.
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Appendix 1. Preferred Reporting Items for Systematic review and Meta-analysis Protocols (PRISMA-P) 2015 Checklist 
Section and topic Item 
No 
Checklist item Page 
Number 
ADMINISTRATIVE INFORMATION  
Title:    
 Identification 1a Identify the report as a protocol of a systematic review 1 
 Update 1b If the protocol is for an update of a previous systematic review, identify as such N/A 
Registration 2 If registered, provide the name of the registry (such as PROSPERO) and registration number 2, 6 
Authors:    
 Contact 3a Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of 
corresponding author 
1 
 Contributions 3b Describe contributions of protocol authors and identify the guarantor of the review 8, 15 
Amendments 4 If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; 
otherwise, state plan for documenting important protocol amendments 
N/A 
Support:    
 Sources 5a Indicate sources of financial or other support for the review 15 
 Sponsor 5b Provide name for the review funder and/or sponsor 15 
 Role of sponsor or 
funder 
5c Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol 15 
INTRODUCTION  
Rationale 6 Describe the rationale for the review in the context of what is already known 4, 5 
Objectives 7 Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, 
comparators, and outcomes (PICO) 
5 
METHODS  
Eligibility criteria 8 Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years 
considered, language, publication status) to be used as criteria for eligibility for the review 
6, 7 
Information sources 9 Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other 
grey literature sources) with planned dates of coverage 
6, 8 
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Study records:    
 Data management 11a Describe the mechanism(s) that will be used to manage records and data throughout the review 8 
 Selection process 11b State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the 
review (that is, screening, eligibility and inclusion in meta-analysis) 
8 
 Data collection 
process 
11c Describe planned method of extracting data from reports (such as piloting forms, done independently, in duplicate), any 
processes for obtaining and confirming data from investigators 
8 
Data items 12 List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data 
assumptions and simplifications 
6, 7, 8 
Outcomes and 
prioritization 
13 List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with 
rationale 
7 
Risk of bias in individual 
studies 
14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the 
outcome or study level, or both; state how this information will be used in data synthesis 
8, 9 
Data synthesis 15a Describe criteria under which study data will be quantitatively synthesised 8, 9 
15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and 
methods of combining data from studies, including any planned exploration of consistency (such as I2, Kendall’s τ) 
8, 9 
15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) 8, 9 
15d If quantitative synthesis is not appropriate, describe the type of summary planned 2, 9 
Meta-bias(es) 16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) 8, 9 
Confidence in cumulative 
evidence 
17 Describe how the strength of the body of evidence will be assessed (such as GRADE) 9 
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Appendix 2. MEDLINE (OVID) search strategy 
1. exp Eye Diseases/   
2. exp Cataract Extraction/   
3. Lens Implantation, Intraocular/   
4. Lenses, Intraocular/   
5. cataract$.tw.   
6. ((intraocular or intra ocular) adj3 lens$).tw.   
7. (IOL or IOLs).tw.   
8. Vision Tests/   
9. Visual Acuity/   
10. exp Refractive Errors/   
11. Visual Fields/   
12. Visual Field Tests/   
13. Contrast Sensitivity/   
14. Depth Perception/   
15. (visual adj2 (acuit$ or field$)).tw.   
16. contrast sensitivity.tw.   
17. (depth perception or stereopsis).tw.   
18. ((impair$ or decreas$ or declin$) adj3 (vision or visual$ or sight$)).tw.   
19. (improv$ adj3 (vision or visual$ or sight$)).tw.   
20. ((visual or vision) adj2 function$).tw.   
21. exp Vision, Ocular/   
22. Vision Screening/   
23. or/1-22   
24. Mass Screening/   
25. ((eye$ or sight or vision or visual$) adj2 (test$ or screen$ or exam$ or diagnos$ or assess$)).tw 
26. 24 and 25   
27. 23 or 26   
28. exp Motor Vehicles/   
29. exp Automobile Driving/   
30. Accidents, Traffic/   
31. (driver$ or driving).tw.   
32. (automobile$ or car or cars or vehicle$).tw.   
33. (motoring or motorcar or "motor car" or "motor cars").tw.   
34. crash$.tw.   
35. ((road or traffic) adj2 injur$).tw.   
36. ((road or traffic or motor) adj2 (accident$ or incident$)).tw.   
37. ((road or traffic or motor) adj2 collision$).tw.   
38. or/28-37   
39. epidemiologic studies/ or case-control studies/ or cohort studies/ or observational study/ or 
follow-up studies/ or longitudinal studies/ or prospective studies/ or retrospective studies/ or 
controlled before-after studies/ or cross-sectional studies/ or historically controlled study/ or 
interrupted time series analysis/   
40. epidemiologic methods/ or focus groups/ or interviews as topic/ or exp "surveys and 
questionnaires"/   
41. epidemiologic research design/ or control groups/ or cross-over studies/ or double-blind 
method/ or meta-analysis as topic/ or network meta-analysis/ or random allocation/ or single-blind 
method/   
42. epidemiologic methods/ or clinical trials as topic/ or feasibility studies/ or multicenter studies as 
topic/ or pilot projects/ or sampling studies/ or twin studies as topic/   
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43. randomized controlled trial/ or controlled clinical trials as topic/ or randomized controlled trials 
as topic/   
44. comparative study/ or evaluation studies/ or meta-analysis/ or review/ or multicenter study/ or 
"systematic review"/ or validation studies/   
45. health surveys/   
46. outcome assessment, health care/   
47. risk factors/   
48. self report/   
49. (population or cohort or observation$ or intervention$ or prospective or retrospective or 
comparative).tw.   
50. (questionnaire$ or survey$).tw.   
51. (randomized or randomised or randomly or RCT).tw.   
52. (systematic review or meta-analysis).tw.   
53. (before adj2 after).tw.   
54. (case$ adj2 control$).tw.   
55. (cross adj1 section$).tw.   
56. or/39-55   
57. 27 and 38   
58. 56 and 57   
59. vehicle-controlled.tw.   
60. (vehicle adj3 inject$).tw.   
61. 59 or 60   
62. 58 not 61   
63. (animal$ or mouse or mice$ or dog or canine or rat or rats or primate$).ti.   
64. (dry eye or cell$ or mutation$ or genes or genome or sequencing).ti.   
65. or/63-64   
66. 62 not 65   
67. limit 66 to english language   
68. exp case reports/   
69. (case adj2 report$).tw.   
70. 68 or 69   
71. 67 not 70   
72. limit 71 to (editorial or letter) 
73. 71 not 72 
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Appendix 3. EMBASE Search Strategy 
 
1. exp eye disease/   
2. exp cataract extraction/   
3. lens implantation/   
4. lens implant/   
5. cataract$.tw.   
6. ((intraocular or intra ocular) adj3 lens$).tw.   
7. (IOL or IOLs).tw.   
8. vision test/   
9. visual acuity/   
10. refractive error/   
11. visual field/   
12. perimetry/   
13. contrast sensitivity/  
14. depth perception/   
15. (visual adj2 (acuit$ or field$)).tw.   
16. contrast sensitivity.tw.   
17. (depth perception or stereopsis).tw.   
18. ((impair$ or decreas$ or declin$) adj3 (vision or visual$ or sight$)).tw.   
19. (improv$ adj3 (vision or visual$ or sight$)).tw.   
20. ((visual or vision) adj2 function$).tw.   
21. vision/   
22. or/1-21   
23. mass screening/   
24. ((eye$ or sight or vision or visual$) adj2 (test$ or screen$ or exam$ or diagnos$ or assess$)).tw.  
25. 23 and 24   
26. 22 or 25   
27. exp car driving/   
28. exp motor vehicle/   
29. traffic accident/   
30. (driver$ or driving).tw.   
31. (automobile$ or car or cars or vehicle$).tw.   
32. (motoring or motorcar or "motor car" or "motor cars").tw.   
33. crash$.tw.   
34. ((road or traffic) adj2 injur$).tw.   
35. ((road or traffic or motor) adj2 (accident$ or incident$)).tw.   
36. ((road or traffic or motor) adj2 collision$).tw.   
37. or/27-36   
38. study design/   
39. controlled clinical trial/   
40. case control study/   
41. cohort analysis/   
42. observational study/   
43. follow up/   
44. longitudinal study/   
45. prospective study/   
46. retrospective study/   
47. epidemiology/   
48. cross-sectional study/   
49. control group/   
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50. crossover procedure/   
51. "meta analysis (topic)"/   
52. network meta-analysis/   
53. randomization/   
54. single blind procedure/   
55. double blind procedure/   
56. "clinical trial (topic)"/   
57. "controlled clinical trial (topic)"/   
58. "randomized controlled trial (topic)"/   
59. "multicenter study (topic)"/   
60. feasibility study/   
61. pilot study/   
62. comparative study/   
63. evaluation study/   
64. multicenter study/   
65. randomized controlled trial/   
66. meta analysis/   
67. "systematic review"/   
68. validation study/   
69. interview/   
70. questionnaire/   
71. outcome assessment/   
72. "systematic review (topic)"/  
73. health survey/   
74. risk factor/   
75. self report/   
76. evidence based practice/   
77. (population or cohort or observation$ or intervention$ or prospective or retrospective or 
comparative).tw.   
78. (questionnaire$ or survey$).tw.   
79. (randomized or randomised or randomly or RCT).tw.   
80. (systematic review or meta-analysis).tw.   
81. (before adj2 after).tw.   
82. (case$ adj2 control$).tw.   
83. (cross adj1 section$).tw.   
84. or/38-83   
85. 26 and 37   
86. 84 and 85   
87. vehicle-controlled.tw.   
88. (vehicle adj3 inject$).tw.   
89. or/87-88   
90. 86 not 89   
91. (animal$ or mouse or mice$ or dog or canine or rat or rats or primate$).ti.   
92. (dry eye or cell$ or mutation$ or genes or genome or sequencing).ti.   
93. or/91-92   
94. 90 not 93   
95. limit 94 to conference abstract status   
96. 94 not 95   
97. limit 96 to english language   
98. exp case report/   
99. (case adj2 report$).tw.   
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100. or/98-99   
101. 97 not 100 
102. limit 101 to (conference paper or "conference review" or editorial or letter or note)  
103. 101 not 102 
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Appendix 4. GLOBAL HEALTH Search Strategy 
 
1. exp eye diseases/   
2. exp vision disorders/   
3. cataract$.tw.   
4. ((intraocular or intra ocular) adj3 lens$).tw.   
5. (IOL or IOLs).tw.   
6. (visual adj2 (acuit$ or field$)).tw.   
7. contrast sensitivity.tw.   
8. (depth perception or stereopsis).tw.   
9. ((impair$ or decreas$ or declin$) adj3 (vision or visual$ or sight$)).tw.   
10. (improv$ adj3 (vision or visual$ or sight$)).tw.   
11. ((visual or vision) adj2 function$).tw.   
12. ((eye$ or sight or vision or visual$) adj2 (test$ or screen$ or exam$ or diagnos$ or assess$)).tw.  
13. or/1-12   
14. drivers/   
15. vehicles/   
16. motor cars/   
17. traffic/   
18. traffic accidents/   
19. (driver$ or driving).tw.   
20. (automobile$ or car or cars or vehicle$).tw.   
21. (motoring or motorcar or "motor car" or "motor cars").tw.   
22. crash$.tw.   
23. ((road or traffic) adj2 injur$).tw.   
24. ((road or traffic or motor) adj2 (accident$ or incident$)).tw.   
25. ((road or traffic or motor) adj2 collision$).tw.   
26. or/14-25   
27. cohort studies/   
28. case-control studies/   
29. longitudinal studies/   
30. retrospective studies/   
31. epidemiology/   
32. exp clinical trials/   
33. randomized controlled trials/   
34. feasibility studies/   
35. pilot projects/   
36. meta-analysis/   
37. systematic reviews/   
38. reviews/   
39. questionnaires/   
40. surveys/   
41. epidemiological surveys/   
42. risk factors/   
43. (population or cohort or observation$ or intervention$ or prospective or retrospective or 
comparative).tw.   
44. (questionnaire$ or survey$).tw.   
45. (randomized or randomised or randomly or RCT).tw.   
46. (systematic review or meta-analysis).tw.   
47. (before adj2 after).tw.   
48. (case$ adj2 control$).tw.   
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49. (cross adj1 section$).tw.   
50. or/27-49   
51. 13 and 26   
52. 50 and 51   
53. (animal$ or mouse or mice$ or dog or canine or rat or rats or primate$).ti.   
54. (dry eye or cell$ or mutation$ or genes or genome or sequencing).ti.   
55. 53 or 54   
56. 52 not 55   
57. limit 56 to english language   
58. case reports/   
59. (case adj2 report$).tw.   
60. 58 or 59   
61. 57 not 60   
62. limit 61 to (conference or conference paper or conference proceedings or correspondence or 
editorial or thesis)   
63. 61 not 62 
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